Related Experiment Video
Updated: Mar 18, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
Making Every Subject Count: A Case Study of Drug Development Path for Medication in a Pediatric Rare Disease
I Bhattacharya1, Z Manukyan2, P Chan3
1Quantitative Clinical Sciences, Pharmatherapeutics, Pfizer Inc, Cambridge, Massachusetts, USA. neil.bhattacharya@pfizer.com.
Abstract:
Approximately 50% of rare diseases are evident in children. Fatal disease prognosis and lack of treatments causes 30% of affected children to not live past their fifth birthday. This clear sense of urgency demands innovation and acceleration in drug development. A case study is discussed highlighting the need for data-rich phase I study design, extensive use of modeling and simulation, use of diverse data sources, and input from collaborators to respond to this urgent call.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Pharmacokinetics in Pediatric Patients: Drug Excretion
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Clinical Trials: Overview

